Atopic Dermatitis

>

Latest News

Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis / image credit courtesy of OHSU
Tapinarof 1% Cream Significantly Improves Patient Reported Outcomes, Including Family QoL, in Atopic Dermatitis

January 27th 2025

Tapinarof 1% cream when used as topical monotherapy led to statistically significant and sustained improvements in QoL, sleep, and other PROs across age groups.

Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis
Self-Reported Symptoms of Topical Steroid Withdrawal Identified in Study of Atopic Dermatitis

January 23rd 2025

New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures / image credit ©InfiniteStudio/AdobeStock
New Study Suggests Patient Benefit Index Complements Traditional Psoriasis Outcome Measures

January 20th 2025

Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist
Atopic Dermatitis pipeline: IND Application Cleared by FDA for Novel Monoclonal Antibody OX40 Antagonist

January 15th 2025

Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment / image credit ©MichaelVI/stock.adobe.com
Phase 2b Clinical Trial of Rezpegaldesleukin in Atopic Dermatitis Achieves Target Enrollment

January 13th 2025

More News

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis / image credit ©InfiniteStudio/stock.adobe.com

Inmagene Announces Favorable Topline Efficacy and Safety Results for IMG-007 in Atopic Dermatitis

Grace Halsey
January 10th 2025

Intravenous IMG-007 at study weeks 0, 2, and 4 led to a mean reduction in EASI of 77% as early as week 4; more than half of participants reached EASI-75 at week 16.

© 2025 MJH Life Sciences

All rights reserved.